WuXi XDC Completes Mechanical Milestone in Singapore, Enhancing Global Bioconjugate Manufacturing Expansion
WuXi XDC Announces Mechanical Completion in Singapore
WuXi XDC Cayman Inc. has officially announced the mechanical completion of its bioconjugates manufacturing site located at Tuas Biomedical Park in Singapore. This significant achievement, which occurred on June 30, 2025, marks a critical step in the global expansion of bioconjugate capabilities. The newly completed facility spans approximately 25,000 square meters, transitioning into the Commissioning and Qualification (CQ) stage as it prepares for operational commencement.
The site is expected to start operations by late 2025, with expectations for Good Manufacturing Practice (GMP) production beginning in 2026. Once operational, WuXi XDC's Singapore facility will provide a comprehensive range of production services, from preclinical development through to commercialization of bioconjugates.
As an essential element of WuXi XDC's global strategy, the Singapore site underscores the company’s commitment to executing projects at the
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.